Clinically sizeable immune-mediated hematologic adverse reactions (such as hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of fewer than one% in patients who been given this drug or were reported with using other PD-1/PD-L1 blocking antibodies.Due to the fact pembrolizumab is cleared from the circulati